Calicheamicins

Enediyne aminoglycosides derived from the bacterium MICROMONOSPORA ECHINOSPORA that are used as antineoplastic antibiotics. They bind to DNA in both healthy and tumor cells, resulting in strand scission and cell death.

Also Known As:

Networked: 122 relevant articles (16 outcomes, 15 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Hamann, Philip R: 10 articles (07/2007 - 01/2002)
2.	Damle, Nitin K: 9 articles (04/2011 - 08/2003)
3.	Boghaert, Erwin R: 7 articles (07/2007 - 03/2004)
4.	Vandendries, Erik: 6 articles (01/2021 - 05/2012)
5.	DiJoseph, John F: 6 articles (04/2011 - 03/2004)
6.	Dougher, Maureen M: 6 articles (04/2011 - 03/2004)
7.	Kunz, Arthur: 6 articles (07/2007 - 03/2004)
8.	Armellino, Douglas C: 5 articles (07/2007 - 03/2004)
9.	DeAngelo, Daniel J: 4 articles (01/2021 - 08/2016)
10.	Kantarjian, Hagop M: 4 articles (01/2021 - 08/2016)

Related Diseases

1.	Neoplasms (Cancer) 01/01/2022 - "We developed an antibody targeting SEZ6 that is rapidly internalized upon receptor binding and, when conjugated to the calicheamicin linker drug, drives potent tumor regression in vitro and in vivo. " 01/01/2022 - "We then screened a patient-derived xenograft library to identify SCLC as a tumor type with enhanced sensitivity to calicheamicin ADCs. " 09/15/2015 - "Anti-EFNA4 Calicheamicin Conjugates Effectively Target Triple-Negative Breast and Ovarian Tumor-Initiating Cells to Result in Sustained Tumor Regressions." 09/01/2011 - "Structural and conformational features relevant to the anti-tumor activity of calicheamicin γ 1I." 01/01/2009 - "Calicheamicin, a potent enediyne, is subsequently released and acts as a cytotoxic anti-tumor agent. "
2.	Acute Myeloid Leukemia (Acute Myelogenous Leukemia) 01/01/2002 - "An anti-CD33 antibody-calicheamicin conjugate for treatment of acute myeloid leukemia. " 03/01/2000 - "Response rates of acute myelogenous leukemia patients treated with the newly developed anti-CD33 antibody-calicheamicin conjugate suggest that at least for a proportion of patients early precursors responsible for re-establishing hematopoiesis are likely to be predominantly normal in origin." 01/01/2019 - "The aim of this study was to characterize the population pharmacokinetics of gemtuzumab ozogamicin, represented by total hP67.6 antibody and unconjugated calicheamicin, in adult patients with acute myeloid leukemia to support drug dosing strategies and explore intrinsic and extrinsic factors that may influence exposure. " 05/01/2009 - "Phase I/II study of humanized anti-CD33 antibody conjugated with calicheamicin, gemtuzumab ozogamicin, in relapsed or refractory acute myeloid leukemia: final results of Japanese multicenter cooperative study." 02/01/2004 - "Multicenter phase II trials with Gemtuzumab Ozogamicin (GO/Mylotarg), consisting of a CD33 antibody linked to the cytotoxic drug calicheamicin, have shown a 30% overall response rate in relapsed acute myeloid leukemia patients. "
3.	Precursor Cell Lymphoblastic Leukemia-Lymphoma (Acute Lymphoblastic Leukemia) 01/01/2019 - "This post hoc exploratory analysis evaluated the relationship between baseline cytogenetics and outcome in patients with relapsed/refractory acute lymphoblastic leukemia (R/R ALL) treated with inotuzumab ozogamicin (InO), a humanized CD22 antibody conjugated to calicheamicin, in the phase 3, open-label, randomized INO-VATE trial. " 10/01/2022 - "Inotuzumab ozogamicin (InO) is a CD22-directed antibody conjugated with calicheamicin approved for adult relapsed or refractory CD22-positive acute lymphoblastic leukemia (ALL). " 01/01/2022 - "Inotuzumab Ozogamicin is a CD22-directed antibody conjugated to calicheamicin, approved in adults with relapsed or refractory (R/R) B cell acute lymphoblastic leukemia (BCP-ALL). " 02/01/2012 - "The novel calicheamicin-conjugated CD22 antibody inotuzumab ozogamicin (CMC-544) effectively kills primary pediatric acute lymphoblastic leukemia cells." 02/01/2003 - "Gemtuzumab ozogamicin in pediatric CD33-positive acute lymphoblastic leukemia: first clinical experiences and relation with cellular sensitivity to single agent calicheamicin."
4.	Leukemia 08/19/2009 - "First, we demonstrate efficacy of calicheamicin θ against primary pre-B leukemic cells and multidrug-resistant leukemia cell lines (IC(50) = 10(-9) to 10(-12) M). " 01/01/2020 - "This agent targets leukemia cells for apoptosis with a cytotoxic payload, calicheamicin, carried by a CD33-specific antibody. " 08/19/2009 - "Eradication of CD19+ leukemia by targeted calicheamicin θ." 06/01/2009 - "AML cell lines and primary blood cells from six patients with acute leukemia were incubated with GO or calicheamicin and the effects on cell viability and proapoptotic signaling were analyzed using MTT assay, flow cytometry, immunofluorescence and immunoblotting. " 01/01/2002 - "It was selectively cytotoxic to HL-60 leukemia cells in tissue culture with an IC(50) in the low to sub-pg cal/mL range (cal = calicheamicin equivalents). "
5.	B-Cell Lymphoma (Lymphoma, B Cell) 01/01/2005 - "Antibody-targeted chemotherapy of B-cell lymphoma using calicheamicin conjugated to murine or humanized antibody against CD22." 07/01/2007 - "CD20-specific antibody-targeted chemotherapy of non-Hodgkin's B-cell lymphoma using calicheamicin-conjugated rituximab." 07/01/2007 - "We investigated whether conjugation to calicheamicin can improve the anti-tumor activity of rituximab against human B-cell lymphoma (BCL) xenografts in preclinical models. " 12/15/2004 - "Potent and specific antitumor efficacy of CMC-544, a CD22-targeted immunoconjugate of calicheamicin, against systemically disseminated B-cell lymphoma." 04/01/2011 - "CMC-544 (inotuzumab ozogamicin) is a CD22-specific immunoconjugate of calicheamicin currently being evaluated in patients with non-Hodgkin's B-cell lymphoma (BCL). "

Related Drugs and Biologics

1.	Inotuzumab Ozogamicin
2.	Gemtuzumab (Mylotarg)
3.	Anti-Bacterial Agents (Antibiotics)
4.	Rituximab (Mabthera)
5.	Monoclonal Antibodies
6.	Immunoconjugates (Immunoconjugate)
7.	Amides
8.	DNA (Deoxyribonucleic Acid)
9.	Acids
10.	Alemtuzumab (Campath)

Related Therapies and Procedures

1.	Drug Therapy (Chemotherapy)
2.	Therapeutics
3.	Immunotherapy
4.	Stem Cell Transplantation
5.	Combination Drug Therapy (Combination Chemotherapy)